ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Praxis Precision Medicines, Inc. (PRAX) stock declined over -4.24%, trading at $36.97 on NASDAQ, down from the previous close of $38.60. The stock opened at $38.20, fluctuating between $36.71 and $39.53 in the recent session.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Employees | 82 |
Beta | 2.67 |
Sales or Revenue | $2.45M |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) stock price is $36.97 in the last trading session. During the trading session, PRAX stock reached the peak price of $39.53 while $36.71 was the lowest point it dropped to. The percentage change in PRAX stock occurred in the recent session was -4.24% while the dollar amount for the price change in PRAX stock was -$1.64.
The NASDAQ listed PRAX is part of Biotechnology industry that operates in the broader Healthcare sector. Praxis Precision Medicines, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Marcio Souza M.B.A.
Pres, Chief Executive Officer & Director
Dr. Steven Petrou B.Sc. (Hons.), Ph.D.
Co-Founder & Chief Scientific Officer
Lauren Mastrocola
Vice President of Fin. & Principal Accounting Officer
Ms. Alyssa J. S. Wyant
Chief Regulatory & Quality Officer
Ms. Kelly McCue
Chief People Officer
Ms. Megan T. Sniecinski
Chief Bus. Officer
Mr. Timothy Edwin Kelly
Chief Financial Officer & Treasurer
Dr. Karl Hansen Ph.D.
Chief Technical Operations Officer
Mr. Alex Nemiroff J.D.
Gen. Counsel & Sec.
PRAX's closing price is 16.93% higher than its 52-week low of $33.01 where as its distance from 52-week high of $91.83 is -57.97%.
Number of PRAX employees currently stands at 82.
Official Website of PRAX is: https://www.praxismedicines.com
PRAX could be contacted at phone 617 300 8460 and can also be accessed through its website. PRAX operates from 99 High Street, Boston, MA 02110, United States.
PRAX stock volume for the day was 407.95K shares. The average number of PRAX shares traded daily for last 3 months was 421.48K.
The market value of PRAX currently stands at $688.95M with its latest stock price at $36.97 and 18.64M of its shares outstanding.